-
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
24 Jan 2025 12:04 GMT
… (TKI) discovered by Eisai, in combination with chemotherapy … of cancers.
About Eisai
Eisai’s Corporate Concept is … Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai … and patents attained by competitors; challenges inherent in …
-
Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval
26 Dec 2024 22:03 GMT
… of Chagas disease.
Eisai overview
Eisai is a pharmaceutical company … include neurology and oncology. Eisai’s major products include … and peripheral neuropathy. Eisai has production plants in … -proof advantage over your competitors.
Be better informed
GlobalData …
-
Insomnia Drugs Business Research Report 2023-2030 Featuring Astellas Pharma, Eisai, Flynn Pharma, Johnson & Johnson, Meda, Merck, Pfizer, Sanofi, and Takeda - ResearchAndMarkets.com
03 Sep 2024 18:32 GMT
… such as Astellas Pharma, Inc., Eisai Co., Ltd., Flynn Pharma Limited …
Insomnia Drugs - Global Key Competitors Percentage Market Share in 2024 … 31 Featured)
Astellas Pharma, Inc.
Eisai Co., Ltd.
Flynn Pharma Limited …
-
Kidney Cancer Drugs Global Strategic Business Report 2023-2030 With Focus on Key Players Including Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, and Pfizer - ResearchAndMarkets.com
22 Aug 2024 05:11 GMT
… AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and more.
Complimentary … Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 … AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
Novartis …
-
Fierce Pharma Asia—BMS, Eisai's ADC divorce; Takeda's US layoffs; House Speaker's BIOSECURE pledge
12 Jul 2024 15:12 GMT
… time, Bristol Myers Squibb returned Eisai's FRα-targeted … 202), which is a potential competitor to AbbVie’s newly bought … exclusive rights in other countries. Eisai now aims to “accelerate the … with inflammatory disease portfolio from Eisai's EA Pharm
…
-
Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod
02 Jul 2024 20:35 GMT
… anti-amyloid therapy—and a competitor to Eisai and Biogen’s Leqembi … for multiple players. Besides, the competitor launch should accelerate the uptake … moment, given that Biogen and Eisai's Leqembi—and Aduhelm …
-
Perampanel API Market Growing Up on Changing Dynamics: Teva Pharmaceutical, Eisai, Qingfeng Pharmaceutical
26 Jun 2024 08:18 GMT
… upcoming challenges and about the competitors.
Key Players in This Report … Pharmaceutical (Israel), Intas Pharma (India), Eisai (Japan), Jiangsu Kangyuan Pharmaceutical (China …
-
Earnings call: Eisai Co. Ltd. maintains steady revenue with a focus on Alzheimer's treatment
17 May 2024 12:09 GMT
… despite the anticipated launch of competitor drug donanemab.
Plans to achieve … ;A Highlights
Eisai highlighted LEQEMBI's unique characteristics against competitors, focusing … account in the plan? The competitor's product may be …
-
Eisai begins rolling submission to FDA for injectable version of Leqembi
15 May 2024 17:28 GMT
… application to be finished. Eisai became eligible to apply via … modelling of observed data. Eisai and Biogen reported data at … in filing.
However, Eisai and Biogen’s major competitor, Eli Lilly, … donanemab. It means that Eisai and Biogen currently enjoy market …
-
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
09 May 2024 16:07 GMT
… well. In 2024, global key competitors share insights into market share … -Obesity Drugs - Global Key Competitors Percentage Market Share in 2024 … Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk …
About
© 1995-2025